✦ LIBER ✦

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

✍ Scribed by Yasuhiro Oki; Hagop M. Kantarjian; Vazganush Gharibyan; Dan Jones; Susan O'Brien; Srdan Verstovsek; Jorge Cortes; Gail M. Morris; Guillermo Garcia-Manero; Jean-Pierre J. Issa

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 161 KB
Volume: 109
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22470

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical course of thrombocytopenia in p

Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia

✍ Hendrik W. van Deventer; Melissa D. Hall; Robert Z. Orlowski; Beverly S. Mitchel 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Phase 1 study of tipifarnib in combinati

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

✍ Jorge Cortes; Alfonso Quintás-Cardama; Guillermo Garcia-Manero; Susan O'Brien; D 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND. The tolerability and efficacy of the combination of tipifarnib, an orally bioavailable nonpeptidomimetic farnesyl transferase inhibitor, and imatinib was investigated in patients with chronic myelogenous leukemia in chronic phase who had failed imatinib. ## METHODS. Tw

Efficacy of imatinib dose escalation in

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

✍ Hagop M. Kantarjian; Richard A. Larson; Francois Guilhot; Stephen G. O'Brien; Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB 👁 1 views

Erratum: Efficacy of imatinib dose escal

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

✍ Hagop M. Kantarjian; Richard A. Larson; Francois Guilhot; Stephen G. O'Brien; Ma 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 1 views

The significance of myelosuppression dur

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

✍ Thomas B. Sneed; Hagop M. Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rio 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression ≥ Grade 3, requiring interruption of thera

Phase 1 study of lonafarnib (SCH 66336)

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

✍ Jorge Cortes; Elias Jabbour; George Q. Daley; Susan O'Brien; Srdan Verstovsek; A 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

## Abstract ## BACKGROUND. Lonafarnib is an orally bioavailable nonpetidomimetic farnesyl transferase inhibitor with significant activity against BCR‐ABL‐positive cell lines and primary human chronic myeloid leukemia (CML) cells. Lonafarnib can inhibit the proliferation of imatinib‐resistant cells